BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Basilea Pharmaceutica 

Grenzacherstrasse 487

Basel    CH-4005  Switzerland
Phone: 41-61-6061-111 Fax: 41-61-6061-112


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
Basilea Pharmaceutica (BSLN.SW)'s Partner Astellas Pharma Inc. (ALPMY) Receives Notification From FDA Of Acceptance Of Filing Of Isavuconazole NDA For The Treatment Of Invasive Aspergillosis And Invasive Mucormycosis 9/8/2014 7:17:05 AM
Basilea Pharmaceutica (BSLN.SW) To Launch Zevtera®/Mabelio®) (ceftobiprole medocaril) In Europe Through A Commercial Services Provider 7/21/2014 1:38:10 PM
Basilea Pharmaceutica (BSLN.SW) Isavuconazole European Marketing Authorization Application For The Treatment Of Invasive Mold Infections 7/17/2014 6:09:09 AM
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Orphan Drug Designations In Europe For The Treatment Of Invasive Mold Infections 7/14/2014 5:57:05 AM
Basilea Pharmaceutica (BSLN.SW)'s Partner Astellas Pharma Inc. (ALPMY) Submits Isavuconazole U.S. NDA For The Treatment Of Invasive Aspergillosis And Invasive Mucormycosis 7/9/2014 2:01:03 PM
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014 7:36:13 AM
FDA Requests More Data For Basilea Pharmaceutica (BSLN.SW)'s Pneumonia Drug Ceftobiprole; Stock Drops -8.15% At Market Close (June 25, 2014) 6/25/2014 6:06:35 AM
Basilea Pharmaceutica (BSLN.SW) Initiates Phase 1 Combination Study With Its Gram-Negative Antibiotic BAL30072 And Meropenem 6/12/2014 7:46:15 AM
Basilea Pharmaceutica (BSLN.SW)'s Oncology Drug Candidate BAL101553 Shows First Evidence Of Antitumor Activity In Phase 1 Study 6/2/2014 9:54:24 AM
Basilea Pharmaceutica (BSLN.SW) Reports Additional Data On Positive Isavuconazole Phase 3 SECURE Study At ECCMID 5/14/2014 9:24:49 AM
12345678910...